CASC9 and breast cancer: Moreover, one study by Jiang et al. [25] has found higher lncRNA CASC9 in epirubicin-resistant breast cancer cells (BCCs) than that in nondrug-resistant BCCs and has also restored the chemical sensitivity of BCCs to epirubicin by knocking down lncRNA CASC9 [25].